Affiliation:
1. Department of Gynaecology. Gynecologic Oncology Unit, Hospital Británico, Montevideo Uruguay
2. Department of Gynaecology and Obstetrics, Ente Ospedaliero Cantonale
3. Università della Svizzera italiana, Lugano, Switzerland
Abstract
Purpose of review
In the past decade, sentinel lymph node (SLN) mapping has progressively substituted full lymphadenectomies in gynecologic oncology. In this article, we review the most relevant and the latest literature on this topic
Recent findings
In endometrial and cervical cancer, the current evidence further support the value of indocyanine green (ICG) as tracer of choice for SLN mapping. Experience in vulvar cancer is more limited, with ICG used together with technetium-99 m (Tc-99m) as a dual tracer but ICG, so far, has not been a game changer in this setting as it has been for cervical and endometrial cancer.
Summary
For most gynecologic cancers, ICG fluorescence imaging is considered now a days the tracer of choice for lymphatic mapping. However, in early-stage vulvar cancer, SLN biopsy with radioactive tracer continues to be the standard-of-care in lymph node status assessment.
Publisher
Ovid Technologies (Wolters Kluwer Health)